Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial by unknown
RESEARCH ARTICLE Open Access
Progression-free and overall survival in
ovarian cancer patients treated with CVac,
a mucin 1 dendritic cell therapy in a
randomized phase 2 trial
H. J. Gray1, B. Benigno2, J. Berek3, J. Chang4, J. Mason5, L. Mileshkin6, P. Mitchell7, M. Moradi8, F. O. Recio9,
C. M. Michener10, A. Alvarez Secord11, N E. Tchabo12, J. K. Chan13, J. Young14, H. Kohrt15, S. E. Gargosky16
and J. C. Goh17*
Abstract
Background: CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune
outcomes of CVac, a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy to patients with
epithelial ovarian cancer (EOC).
Methods: Patients (n = 56) in first (CR1) or second clinical remission (CR2) were randomized (1:1) to standard of
care (SOC) observation or CVac maintenance treatment. Ten doses were administered over 56 weeks. Both groups
were followed for progression-free survival (PFS) and overall survival (OS).
Results: Fifty-six patients were randomized: 27 to SOC and 29 to CVac. Therapy was safe with only seven patients
with Grade 3–4 treatment-emergent adverse events. A variable but measurable mucin 1 T cell-specific response was
induced in all CVac-treated and some standard of care (SOC) patients. Progression free survival (PFS) was not
significantly longer in the treated group compared to SOC group (13 vs. 9 months, p = 0.36, hazard ratio [HR] = 0.
73). Analysis by remission status showed in the CR1 subgroup a median PFS of 18 months (SOC) vs. 13 months
(CVac); p = 0.69 (HR = 1.18; CI 0.52–2.71). However CR2 patients showed a longer median PFS in the CVac-treated
group (median PFS not yet reached, >13 vs. 5 months; p = 0.04, HR = 0.32 CI). OS for CR2 patients at 42 months of
follow-up showed a difference of 26 months for SOC vs. > 42 months for CVac-treated (as median OS had not
been reached; HR = 0.17 (CI 0.02–1.4) with a p = 0.07).
Conclusions: CVac, a mucin 1-dendritic cell maintenance treatment was safe and well tolerated in ovarian cancer
patients. A variable but observed CVac-derived, mucin 1-specific T cell response was measured. Notably, CR2
patients showed an improved PFS and lengthened OS. Further studies in CR2 ovarian cancer patients are warranted
(NCT01068509).
Trial registration: NCT01068509. Study Initiation Date (first patient screened): 20 July 2010. Study Completion Date
(last patient observation): 20 August 2013, the last patient observation for progression-free survival; 29 April 2015,
the last patient was documented regarding overall survival.
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Background
Ovarian cancer is typically managed by surgical cyto-
reduction followed by platinum and taxane-based
chemotherapy. While the majority of patients achieve a
clinical remission from this initial therapy, more than
70 % will subsequently develop recurrent disease [1].
Immunotherapeutic approaches to cancer rely on
stimulation of the immune system to specifically target
and destroy tumors. Mucin proteins are promising
targets for immunotherapy; in particular, the epithelial
mucin surface antigen 1 is overexpressed in adenocar-
cinomas in an aberrant form [2–5]. Prior literature
have described high levels of MUC1 expression (100 %)
in ovarian adenocarcinomas [6] and in late-stage
epithelial ovarian cancer (EOC), tumor cells will signifi-
cantly overexpress mucin 1 showing a significant asso-
ciation between mucin 1 over-expression, histological
grade and clinical stage [7, 8]. Therefore, mucin 1 is a
specific and appropriate target as an immunotherapy
for EOC, whereby the immune system is stimulated to
target and destroy tumor cells.
A dendritic cell vaccine targeting the MUC-1 glyco-
protein was developed (termed CVac). Prior to the
current trial, two clinical trials were conducted with
CVac. In the phase I trial, 17 subjects (three healthy
volunteers and 14 advanced solid tumor patients) were
enrolled, the purpose of which was to establish safety
and to observe host immunologic responses. Two of
these patients had ovarian cancer, with one patient sur-
viving beyond 12 months post-therapy despite advanced
disease. Regarding safety, no anaphylactic reactions were
observed and all patients measured a CVac-specific T
cell response as measured by ELISpot. No dose limiting
toxicities (DLTs) or serious adverse events (SAEs) attrib-
utable to CVac were reported in the Phase I study [9].
Subsequently, a phase 2a trial administered CVac to
advanced EOC patients who were experiencing pro-
gression of disease and for whom standard therapy was
no longer available [10]. All 28 patients recruited were
evaluable for safety and 26 for efficacy. All had under-
gone surgery and platinum-based chemotherapy, and
57 % of patients received ≥ 3 chemotherapy regimens.
There were no Grade 3 or 4 toxicities considered
related to CVac. Despite heavy pre-treatment, four
patients showed CA-125 response or stabilization; two
patients with major responses defined as > 50 % reduc-
tion in CA-125, that were sustained for 10 weeks and
42 weeks, respectively [11]. The median duration was
10.3 months (5.3–16.3 months).
Given the promising results from these trials, a clinical
trial with ovarian cancer patients with a low tumor
burden following chemotherapy were considered for
CVac as a maintenance strategy. Subsequently, the trial
CAN-003 was designed as a randomized, multi-center
international trial with global manufacturing to evaluate
the safety and efficacy of CVac in EOC patients in first




Patients enrolled into the trial were female ≥ 18 years old
with histologically confirmed Stage III or IV epithelial
ovarian, primary peritoneal, or fallopian tube cancer
who had previously underwent surgical cytoreduction,
received first- or second-line conventional chemother-
apy, and were in complete remission (CR). CR was
defined as no clinical or radiologic evidence of disease
and CA-125 below the upper limit of normal (ULN),
according to the local laboratory.
CA-125 ≤ upper limit of normal (ULN) with a prior
history of an elevated CA-125 was required with not
more than 12 weeks between enrollment and the last
dose of chemotherapy that resulted in a CR.
Exclusion criteria included ovarian germ cell, sarcoma,
or mixed Müllerian tumors, or coexisting or other
malignancies unless in CR for at least 3 years, but did
not include in-situ carcinoma of the cervix or basal cell
or squamous cell carcinoma of the skin, assuming they
had been adequately treated. Other exclusion criteria
included any active uncontrolled infections or any organ
system toxicity ≥Grade 2 by CTCAE criteria.
Study design
This was a randomized, open-label, multinational, Phase
2b trial evaluating the safety and efficacy of CVac
administered as a single agent for the maintenance treat-
ment of EOC. Eligible patients had achieved CR follow-
ing conventional chemotherapy and were enrolled after
signing informed consents. Ethics and Review board
details are at the end of the manuscript.
Manufacturing was transferred from Australia to the
US, and as a quality measure, an initial cohort of seven
patients who met the study eligibility criteria were not
randomized but given one CVac treatment of a total of 6
to 8 injections at four anatomical sites and followed for
at least 28 days. This was called the non-randomized
CVac cohort (NR-CVac) and they were not included in
the efficacy outcome analysis. After the manufacturing
characteristics were confirmed to be consistent between
facilities, each NR-CVac patient completed one treat-
ment. After 30 days, no serious or treatment-related
Grade 3 or 4 adverse events (TEAEs) were reported,
patients (N = 56) were then enrolled to randomization
between standard of care observation versus CVac. All
patients who were assigned to receive CVac underwent
leukapheresis to collect mononuclear cells (MNCs).
Approximately 500 to 800 × 10^6 blood monocytes were
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collected, and if insufficient cells were obtained, add-
itional leukapheresis procedures were performed. The
leukapheresis product was shipped to the manufacturer,
and each patient’s MNCs were enriched using cell separ-
ation techniques.
For CVac manufacturing, the drug substance, DC-M-
FP, was composed of three starting materials: the pa-
tient’s autologous dendritic cells (DCs), Mannan (M)
and Fusion Protein (FP) to create DC-M-FP. The struc-
tural features of each component were: DCs were differ-
entiated from a patient’s peripheral blood mononuclear
cells (PBMC or MNC), also referred to as the Mono-
nuclear Cell Product (MNC Product). The MNCs were
collected by leukapheresis in certified, inspected and
approved leukapheresis units and manufactured under
Good Manufacturing Practices (GMP) conditions associ-
ated with cells being fractionated and cultured in the
presence of cytokines (GM-CSF and IL-4) to promote
the differentiation of MNC to DCs. M-FP was the
antigen obtained when mannan was oxidized, to form
aldehyde groups, and coupled to the FP. M-FP was com-
posed of two parts; (1) mannan, a polymannose with
molecular weight of approximately 60 kDa and (2) FP, a
recombinant human fusion protein (mucin 1-glutathione
S-transferase) with a molecular weight of approximately
38 kDa which was composed of two distinct moieties of
a 110 amino acid fragment (12 kDa) of the mucin 1
protein, which was derived from the variable number of
tandem repeats (VNTR) region of the mucin 1 protein;
and a glutathione S-transferase, a 26 kDa protein.
The patient’s cells were cultured for 5 days with
granulocyte-macrophage colony-stimulating factor and
interleukin-4 to cultivate the maturation of MNCs to
DCs. The culture was treated overnight with the
antigen, M-FP, to arm the DCs to the specific mucin 1
antigen creating the DC-M-FP. After washing and
formulating in HSA and DMSO at an approximate
concentration of 60 × 10^6 DCs/mL, the vials then
contained CVac. CVac was cryopreserved and stored in
the vapor phase of liquid nitrogen at the manufacturing
facility until required [9, 10].
Patients were given 10 doses of CVac, with the first 7
doses administered every 4 weeks and then the last 3
doses administered every 8 weeks. Patients in the SOC
group did not undergo leukapheresis nor interventional
treatment, but attended the same visit schedule as
treated patients.
Patients who completed the first 56 weeks of the study
(10 doses of CVac) without disease progression contin-
ued to be followed every 12 weeks for an additional
48 weeks until an end-of-study (EOS) PFS visit. All pa-
tients were followed for survival until the study closed.
A total of 60 patients were originally planned for
recruitment for this study. This sample size for this
exploratory Phase 2 study was considered adequate on
clinical grounds to evaluate trends in immunological
Fig. 1 Patient Consort. Patients received 10 doses up till week 56 and were subsequently followed until week 104. Week 104 defined the end
of study
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outcomes, disease markers, rates of tumor progression,
and other clinical outcomes for the purpose of planning
future trials.
Endpoints and assessments
The primary measure of efficacy was the duration of PFS
defined as the date of randomization to the date of doc-
umented progression of disease (PD), or death from any
cause. PD was defined as either of the following:
(a)Two serum values of CA-125 ≥ 2× ULN performed
at least 1 week apart based on Gynecologic Cancer
Intergroup (GCIG) criteria [11]
(b)Increasing clinical and/or radiological evidence of
disease since study entry regardless of serum
CA-125 per Response Evaluation Criteria in Solid
Tumors (RECIST 1.1) criteria [12]
Secondary endpoints included OS as measured from
date of randomization to date of death, from any cause
and the evaluation of host immunologic outcomes sub-
sequent to CVac administration.
Radiological scans
A CT or MRI scan of the chest, abdomen, and pelvis
were performed at screening/baseline, after the timing
period of three treatments, and every 12 weeks until the
end of the study. RECIST version 1.1 guidelines were
used to evaluate CT or MRI results for assessment of
patient response [11, 12].
Immunological tests
Serum was collected for assessment of mucin 1 anti-
bodies by ELISA and whole blood for intracellular cyto-
kine staining (ICS) assays at screening/baseline, week
20, and every 12 weeks until the end of the study in
both groups [13]. Testing was performed at a central
USA laboratory (HIMC, Stanford, CA). For the ICS
assays, using eight-color flow cytometry IFNg, TNFa,
IL-2, IL-4, and IL-17-producing CD4+ and CD8+ T
cells were measured with and without mucin 1 peptide
challenge [13, 14].
Mucin 1 antibody and ICS assays were performed to
assess the humoral and cellular immunological responses,
respectively.
Safety assessments
Safety was assessed from documentation of AEs, clinical
laboratory results (routine hematology, biochemistry and
urinalysis), auto-antibody screening, physical examin-




Excluding the seven patients treated in the non-
randomized lead-in cohort (NR), there were 56 patients
randomized to CVac (N = 29) and SOC (N = 27). Figure 1
outlines patient disposition. Three patients withdrew
consent, one patient was lost to follow-up, and one pa-
tient was withdrawn for other reasons; none of these five
patients had a PFS event. Patients who withdrew consent
included 2 SOC patients and 1 CVac patient who did
not receive any study treatment. Patient demographics
were similar between the patient groups (Table 1).
Most patients had Stage III cancer at the time of diag-
nosis and had serous tumor histology (86.2 % in the
CVac group and 85.2 % in the SOC group). Cytoreduc-
tive surgery was optimal in most patients in the trial
with 81 % CR1 and 90 % CR2 patients. All patients
Table 1 Patient Characteristics
NR CVac SOC
(N = 7) (N = 29) (N = 27)
Age, years
Mean (SD) 52.4 (10.3) 56.8 (8.5) 56.2 (9.5)
Median (min, max) 49 (43–70) 58 (34–75) 55 (40-74)
Race, n (%)
White 7 (100.0 %) 26 (89.7 %) 23 (85.2 %)
Asian 0 3 (10.3 %) 2 (7.4 %)
Black or African American 0 0 2 (7.4 %)
Ethnicity, n (%)
Hispanic or Latino 0 0 1 (3.8 %)
Not Hispanic or Latino 7 (100.0 %) 29 (100.0 %) 25 (96.2 %)
Cancer stage at enrollment, n (%)
III 5 (71 %) 24 (83 %) 20 (74 %)
IV 2 (29 %) 5 (17 %) 7 (26 %)
Histology, n (%)
Serous 5 (71 %) 25 (86 %) 23 (85 %)
Clear cell 1 (14 %) 0 0
Endometrioid 0 1 (3 %) 2 (7 %)
Mixed, serous 0 1 (3 %) 0
Mucinous 0 1 (3 %) 1 (4 %)
Other 1 (14 %)a 0 0
Other, mixed 0 1 (3 %)b 1 (4 %)c
Cytoreductive Surgery
Optimal 7 (100 %) 26 (90 %) 21 (78 %)
Sub-optimal 0 (0 %) 3 (10 %) 6 (22 %)
aAdenocarcinoma, Primary Mullerian carcinoma
bLeft ovary high grade adenocarcinoma with mixed clear cell and
serous features
cOvarian Adenocarcinoma, Mixed Serous & Transitional cell type Grade 3: solid
& focally papillary
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received taxane and platinum therapy as first line, with
only three patients documented treated with intraperito-
neal (IP) chemotherapy.
Dosing
Of the seven patients in the lead-in, non-randomized
cohort (NR), four patients completed the series of ten
treatments with CVac. All three patients who did not
complete the planned dosing series were discontinued
for disease progression, including one patient each who
received either 2, 4 or 6 doses.
Of the 26 patients who were randomized to CVac
46 % received all 10 doses while 77 % received 6 or more
doses. The remaining breakdown of CVac doses was one
patient received 9 doses, five patients received 7 doses,
two patients received 6 doses, three patients received 4
doses, two patients received 2 doses, and one patient
received 1 dose.
Safety
Both the randomized and non-randomized cohorts were
assessed for safety. Common treatment-emergent AEs
(TEAE) seen in greater than 10 % of the patients were
unremarkable, similar among groups and generally grade
1–2. Grade 3 or 4 TEAE included:
– EOC metastases to the liver that resulted in
discontinuation;
– urinary tract infection, generalized pruritus, cough,
headache, and bunion;
– sinusitis, small intestinal obstruction, and disease
progression;
– febrile neutropenia;
– small intestinal obstruction;
– abdominal pain, diarrhea, and meniscus lesion
(Table 2).
The investigator associated causality of these TEAEs
stated that generalized pruritus and headache were
considered probably and possibly related to CVac, re-
spectively. Seven patients had a total of 9 SAEs during
the study (4 CVac patients 3 SOC patients), including
one SAE in a SOC patient resulting in death (subdural
hematoma in a patient with a medical history of hyper-
tension, right ventricular thrombus and myocardial
infarction). The 4 CVac patients with SAEs included
abdominal pain and metastatic EOC; small intestinal
obstruction and disease progression; disease progres-
sion with later hospitalization for febrile neutropenia
was due to subsequent chemotherapy after progression
on CVac. Progression of metastatic EOC in the patient re-
sulted in interruption of treatment and discontinuation
Table 2 Treatment-Emergent Adverse Events with Severity Grade 3 or 4 for Patients with CR Following First- or Second-Line Therapy
(Safety Population)
NR-CVac CVac SOC Total
(N = 7) (N = 26) (N = 24) (N = 57)
Patients with TEAE of Severity 3 or 4 0 (0 %) 7 (27 %) 2 (8 %) 9 (16 %)
Small intestinal obstruction 0 (0 %) 2 (8 %) 0 (0 %) 2 (4 %)
Abdominal pain 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Alanine aminotransferase increased 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Arthralgia 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Bunion 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Cough 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Diarrhea 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Disease Progression 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Escherichia urinary tract infection 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Febrile neutropenia 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Gamma-glutamyltransferase increased 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Hand fracture 0 (0 %) 0 (0 %) 1 (4 %) 1 (2 %)
Headache 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Meniscus lesion 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Metastases to liver 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Ovarian epithelial cancer metastatic 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Pruritus generalized 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
Sinusitis 0 (0 %) 1 (4 %) 0 (0 %) 1 (2 %)
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from the study. All SAEs were considered unrelated to the
treatment.
One patient was discontinued from the study for AE
of EOC metastases to the liver that occurred 13 months
after the first dose and 2 months after the last dose of
CVac treatment. The AE of EOC metastases was consid-
ered unrelated to CVac.
Immuno-assay
Mucin 1 antibodies measured from blood samples
throughout the study were assessed by a quantitative
ELISA [13]. Mean mucin 1 antibody levels were low and
did not notably change with treatment throughout the
study. Only two patients who were in the SOC group
showed a low anti-mucin 1 response possibly as a result
of an endogenous response to tumor expression. No
anti-mucin 1 immune activity was measured in the CVac
treated patients (data not shown).
To assess T cell responses, intracellular cytokine
staining data were measured from PBMC at screening/
baseline, Week 20, and every 12 weeks until the end of
the study in both groups. SOC patients’ T cells measured
a small or absence of response when challenged with
mucin 1 [14]. However, CVac-treated patients had T
cells that responded to mucin 1 challenge seen with both
CD4+ (helper T cells) and CD8+ (killer T cells). In this
cohort of patients, CD8+ cytotoxic T cells showed a
greater reactivity than CD4+ T helper cells. Kinetics of
intracellular cytokine (ICS) expression were difficult to
determine due to a wide variability in this small patient
cohort. At the end of dosing (visit 13 after 10 doses in
total; Fig. 2) there remained a detectable mucin 1-
specific T cell response in treated patients as compared
to SOC that was measurable over endogenous baseline




At the end of 48 weeks of PFS follow up, CVac treated
patients showed a median PFS of 13 months as com-
pared to 9 months for the SOC group (hazard ratio [HR]
Fig. 2 Intracellular cytokine staining (ICS) of CVac-treated patients. Values are corrected for the background (endogenous unstimulated response)
subtracted from the mucin 1 (MUC1) challenge shown as a percentage. Values of zero or less are shown as zero. The samples shown represent
those patients that had both a baseline sample and a visit 13 sample (completion of 10 doses of CVac treatment) available for analysis
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of 0.72, p = 0.33 CI 0.38–1.38). Given the heterogeneity
in the enrolled population, subgroup analysis was per-
formed to determine if there was a differential survival
benefit for CVac treated patients based on their remis-
sion status (CR1 vs. CR2).
Analysis of the patients in CR1 revealed no signifi-
cant difference in PFS between the CVac and SOC
subjects (13 vs. 18 months) (HR = 1.18; CI 0.52–2.71;
p = 0.69) (Fig. 3). However, as patients were enrolled
within 12 weeks of their last chemotherapy, evaluation
of the PFS curves suggested that 8 of 36 (22 %)
patients progressed at ≤ 6 months, consistent with
primary platinum-resistance in the CR1 cohort. In the
CR2 cohort the median PFS for CR2 patients treated
with CVac (N = 10) was greater than 13 months;
compared to the SOC control group (N = 10) was
5 months, an observed hazard ratio of 0.32 (CI 0.10–
1.03; p = 0.04).
Fig. 3 Progression-free survival. Progression-free survival was defined as the time from date of randomization to the earlier of disease progression or
death due to any cause. Vertical tick marks represent the progression-free survival time of patients without disease progression. Hazard ratio (CVac/
SOC) was estimated using a Cox proportional hazards model. P-value was calculated using the log-rank test. a Progression-free survival for patients in
complete remission after first-line therapy; CR1. b Progression-free survival for patients in complete remission after second-line therapy; CR2
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Overall survival
OS was followed until 43 months and the median OS
was not reached in either arm for the overall population
(HR = 0.38, p = 0.06, 95 %; data not shown). Sub-analysis
of remission status showed in CR1 patients that after
40.5 months of follow up, a median OS was not reached
[15] (Fig. 4). CR2 patients at 42 months of follow up
showed that the SOC patients had attained a median OS
of 26 months consistent with general literature estimates
of 24–29 months [15–17]. Patients administered CVac
Fig. 4 Overall Survival. Overall survival was defined as the time from date of randomization to the date of death due to any cause. Vertical tick marks
represent the overall survival time of patients reported alive or lost to follow-up as of the last contact. Hazard ratio (CVAC/OSC) was estimated using a
Cox proportional hazards model. P-value was calculated using the log-rank test. a Overall survival for patients in complete remission after
first-line therapy; CR1. b Overall survival for patients in complete remission after second-line therapy; CR2
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had not reached median overall survival, which sug-
gested an increase of > 16 months in this cohort.
Conclusion
The treatment of EOC has been filled with approaches
that have resulted largely in PFS benefit in the biologic
era with front-line maintenance +/−concurrent anti-
VEGF therapies (bevacizumab, pazopanib, nintedanib
[15–18]) but not median overall survival (OS) benefit to
date. Some will argue that the availability of multiple
lines of subsequent therapies and cross-over effect may
account for this observation. The only randomized phase
3 trial to show an preliminary OS benefit to date with a
multi-targeted anti-VEGF agent (cediranib) is ICON-6,
in the recurrent platinum-sensitive setting. There are
also phase 3 trials in the concurrent and/or switch-
maintenance setting with poly-ADP ribose polymerase
inhibitors (PARPi) in the high-grade serous and endome-
triod histological sub-groups; these trials are ongoing or
awaiting maturity [19–22]. As we move into the era of
immuno-oncology we are hopeful that a clearly demon-
strable OS benefit is finally within grasp in the near
future.
This trial evaluated CVac, a DC immunotherapeutic
approach targeting mucin 1 in EOC. EOC patients in
first and second clinical remission had immune systems
that elicited a cellular, mucin 1 specific T cell response
and not a humoral response to treatment. CVac was well
tolerated and safe with the majority of TEAE as grade
1–2 with similar distribution in both groups (fatigue,
abdominal pain, diarrhea and nausea).
Although this study was designed as an exploratory
phase 2 trial, overall we found patients treated with
CVac compared to observation had no improvement in
PFS or OS. However, in the sub-group analysis, patients
in CR2 treated with the dendritic cell vaccine, CVac,
showed an improvement in both PFS and OS. Addition-
ally, we observed the PFS curves in CR2 patients to have
a typical shape in cancer immunotherapy. First, there
was the classic delayed effect with no difference between
treatment arms during the first 4–5 months of the study.
Then, we observed a significant “long tail” indicating
that the CVac patients who may have responded stayed
in remission for an extended time. Notably, this study
was small, with inherent biases of a randomized phase 2
trial; therefore a larger phase 3 trial is required to be
more definitive.
To explain the survival differences observed between
CR1 and CR2 patients with maintenance CVac, we
hypothesized that the CR2 group of patients was a much
more homogenous group, and all likely primary plat-
inum sensitive. We noted a 22 % primary platinum
resistance in the CR1 patients. CR2 patients may have
represented a better prognostic group overall and
perhaps responded more likely to immunotherapy as a
maintenance strategy. Neither Provenge nor Yervoy (two
approved immunotherapeutics for metastatic prostate
cancer and melanoma, respectively) demonstrated a dif-
ference in PFS as compared to the control arm in their
phase 3 trials; both demonstrated clinically significant
and statistically significant differences in OS.
Several recently presented phase 3 trials with im-
mune check-point inhibitors (largely with anti-PD1
antibodies, nivolumab or pembrolizumab); have shown
a significant prolongation in OS in metastatic melan-
oma, clear-cell renal cell carcinoma (2nd-line) and
non-small cell lung cancer, further supporting the role
of immunotherapeutics in solid tumors. Immunother-
apies have become an important part of treating sev-
eral types of cancer; the indication for which is
growing. The safety profile shown with CVac, and the
improved outcomes of PFS and OS were encouraging
and worthy of further study.
Abbreviation
AE: adverse event; CR1: first clinical remission; CR2: second clinical remission;
CVac: DCs treated with a mannosylated recombinant human fusion protein
comprised of mucin 1- glutathione S-transferase; DC: dendritic cell;
EOC: epithelial ovarian cancer; HR: hazard ratio; ICS: intracellular cytokine
staining; IFNγ: interferon gamma; IL: interleukin; M-FP: mannosylated
recombinant human fusion protein comprised of mucin 1-glutathione S-
transferase; NR: non randomized; OS: overall survival; PBMC: peripheral blood
mononuclear cel; PD: progressive disease; PFS: progression-free survival;
SAE: serious adverse event; SOC: standard of care; TEAE: treatment emergent
adverse event; TNFα: tumor necrosis factor alpha; ULN: upper limit of normal.
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